PDCD1 and head and neck squamous cell carcinoma: Finally, encouraging results were seen in a recent phase Ib trial of neo-adjuvant SBRT and anti-PD-1 therapy in HNSCC (NCT03247712), where the combination was seen to be well tolerated with a high rate of major pathological response (86%) (123).